Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer
David Aggen, MD, PhD, identifies dosing strategies that may maximize treatment efficacy while minimizing toxicity in patients with kidney cancer.
Recent Videos
Related Content
Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors
José Luis Rodríguez-Olivares, MD;Héctor Raúl González-Sánchez, MD;Evelyn Lilian Beas-Lozano, MD;Jazmin Arteaga-Vázquez, MD;Elaine T. Lam, MD;María T. Bourlon, MD, MSc, FASCO
October 22nd 2024Article
A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.
